Rapport Therapeutics reported striking Phase 2 data for its experimental epilepsy drug RAP-219, showing a median 78% reduction in seizure frequency across 30 patients. The open-label trial used implant-based brain activity measures and clinical observations, surpassing typical placebo responses significantly. Following these results, the company plans two Phase 3 trials next year, propelling its valuation above $1 billion. Analysts from Stifel and Jefferies highlighted RAP-219’s potential as a best-in-class focal onset seizure therapy, marking a notable advance for neurology-focused drug development. The data represent a promising milestone in epilepsy treatment strategies.